Insiders Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:02 13/03/2026 am IST			After hours 05:30:00 am
977.25 ^USD	-2.26%		980.47	+0.33%

13/03	Eli Lilly warns of impurity in compounded versions of its drug Zepbound
12/03	Eli Lilly's Japanese Unit to Invest $126 Million to Bolster Capacity at Kobe Facility	MT

Insiders

12/03	Global markets live: Tesla, JPMorgan, Amazon, Leonardo…
11/03	Hims & Hers Health, Inc. Appoints Kathryn Beiser as Chief Communications Officer	CI
09/03	Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB…
26/02	Soleno Therapeutics Names New Chief Financial Officer	MT
24/02	Novo's stumbles burnish Lilly's widening lead in weight-loss drugs	RE
24/02	Tectonic Therapeutic, Inc. Announces Board and Committees Changes	CI
23/02	Zura Bio Limited Announces Board Changes, Effective February 21, 2026	CI
19/02	Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors	CI
17/02	Integra Lifesciences Holdings Corporation Announces Appointments of Executives	CI
09/02	Global markets live: Alphabet, Meta, Eli Lilly, Uber, Ocado…
09/02	Wall St struggles for direction as investors await key economic data	RE
09/02	PRESS DIGEST-Wall Street Journal - February 9	RE
04/02	Top Midday Stories: Lilly Shares Soar After Strong Q4 Earnings, Guidance; Uber Q4 EPS Misses Target, CFO Stepping Down	MT
04/02	Wall St selloff deepens led by software, cloud firms	RE
03/02	Bicycle Therapeutics plc Announces Executive Changes	CI
28/01	Vera Therapeutics Announces Appointment of Matt Skelton as Chief Commercial Officer, Effective January 28, 2026	CI
14/01	Oncolytics Biotech Inc. Appoints Yujun Wu as Vice President, Head of Biostatistics	CI
13/01	Gan & Lee Pharmaceuticals Appoints Dr. John Wang As Senior Vice President And Chief Strategy Officer, Effective January 12, 2026	CI
12/01	Analyst recommendations: Exxon Mobil, AbbVie, Eli Lilly, JD Sports…
12/01	Kyverna Therapeutics, Inc. Appoints Christi Shaw as Executive Chairperson of the Board, Effective January 12, 2026	CI
12/01	Juvena Therapeutics, Inc. announced that it has received $33.5 million in funding from Bison Ventures, Jefferson Life Sciences, Mubadala Capital, Manta Ray Ventures LLC, Eli Lilly and Company	CI
08/01	Xilio Therapeutics, Inc. Announces Change of Chair of the Board of Directors	CI
07/01	Mediar Therapeutics, Inc. announced that it has received $76 million in funding from Amplitude Ventures Inc., ICG America, Inc., Longwood Fund, Asahi Kasei Pharma America Corporation, Alexandria Real Estate Equities, Inc.	CI
07/01	Viking Therapeutics, Inc. Announces Appointment of Neil Aubuchon as Chief Commercial Officer	CI
05/01	Novo Nordisk's US public affairs head leaves company, memo shows	RE